APO Research
Talk to an analyst

APO RESEARCH · REPORT

Exosome CDMO

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Exosome CDMO Market Analysis and Forecast 2026-2032

1 January 2026208 pages

Choose your research edition.

Industry ResearchExosome CDMO Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Exosome CDMO Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Exosome CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Exosome CDMO Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Exosome CDMO Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Exosome CDMO market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Exosome CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Exosome CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Exosome CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Exosome CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Exosome CDMO include REPROCELL, Histocell, Lonza, MYCENAX, RoosterBio, Altaris LLC, Asahi Glass Co., Fortis Life Sciences and Scorpius BioManufacturing, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Exosome CDMO, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Exosome CDMO, also provides the revenue of main regions and countries. Of the upcoming market potential for Exosome CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Exosome CDMO revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Exosome CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Exosome CDMO revenue, projected growth trends, production technology, application and end-user industry.

Exosome CDMO Segment by Company

REPROCELL

Histocell

Lonza

MYCENAX

RoosterBio

Altaris LLC

Asahi Glass Co.

Fortis Life Sciences

Scorpius BioManufacturing

Miltenyi Bioindustry

Exothera

EXO Biologics

Porton Advanced

Elise Biopharma

Evox Therapeutics

FUJIFILM Biotechnologies

Exosome CDMO Segment by Type

Preclinical CRO

Clinical CRO

Exosome CDMO Segment by Application

Laboratory

Universities

Bio Industry

Medical Industry

Exosome CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Exosome CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Exosome CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Exosome CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Exosome CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Exosome CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Exosome CDMO revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Exosome CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Preclinical CRO Major Player Table 3. Clinical CRO Major Player Table 4. Global Exosome CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Laboratory Major Player Table 6. Universities Major Player Table 7. Bio Industry Major Player Table 8. Medical Industry Major Player Table 9. Exosome CDMO Industry Trends Table 10. Exosome CDMO Industry Drivers Table 11. Exosome CDMO Industry Opportunities and Challenges Table 12. Exosome CDMO Industry Restraints Table 13. Global Exosome CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Exosome CDMO Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Exosome CDMO Market Share by Region (2021-2026) Table 16. Global Exosome CDMO Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Exosome CDMO Market Share by Region (2027-2032) Table 18. Global Exosome CDMO Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Exosome CDMO Revenue Market Share by Players (2021-2026) Table 20. Global Exosome CDMO Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Exosome CDMO Key Players Headquarters & Area Served Table 22. Global Exosome CDMO Players, Product Type & Application Table 23. Global Exosome CDMO Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Exosome CDMO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Exosome CDMO Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Exosome CDMO Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Exosome CDMO Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Exosome CDMO Revenue Market Share by Type (2021-2026) Table 30. Global Exosome CDMO Revenue Market Share by Type (2027-2032) Table 31. Global Exosome CDMO Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Exosome CDMO Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Exosome CDMO Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Exosome CDMO Revenue Market Share by Application (2021-2026) Table 35. Global Exosome CDMO Revenue Market Share by Application (2027-2032) Table 36. REPROCELL Company Information Table 37. REPROCELL Business Overview Table 38. REPROCELL Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. REPROCELL Exosome CDMO Product Portfolio Table 40. REPROCELL Recent Development Table 41. Histocell Company Information Table 42. Histocell Business Overview Table 43. Histocell Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Histocell Exosome CDMO Product Portfolio Table 45. Histocell Recent Development Table 46. Lonza Company Information Table 47. Lonza Business Overview Table 48. Lonza Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Lonza Exosome CDMO Product Portfolio Table 50. Lonza Recent Development Table 51. MYCENAX Company Information Table 52. MYCENAX Business Overview Table 53. MYCENAX Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. MYCENAX Exosome CDMO Product Portfolio Table 55. MYCENAX Recent Development Table 56. RoosterBio Company Information Table 57. RoosterBio Business Overview Table 58. RoosterBio Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. RoosterBio Exosome CDMO Product Portfolio Table 60. RoosterBio Recent Development Table 61. Altaris LLC Company Information Table 62. Altaris LLC Business Overview Table 63. Altaris LLC Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Altaris LLC Exosome CDMO Product Portfolio Table 65. Altaris LLC Recent Development Table 66. Asahi Glass Co. Company Information Table 67. Asahi Glass Co. Business Overview Table 68. Asahi Glass Co. Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Asahi Glass Co. Exosome CDMO Product Portfolio Table 70. Asahi Glass Co. Recent Development Table 71. Fortis Life Sciences Company Information Table 72. Fortis Life Sciences Business Overview Table 73. Fortis Life Sciences Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Fortis Life Sciences Exosome CDMO Product Portfolio Table 75. Fortis Life Sciences Recent Development Table 76. Scorpius BioManufacturing Company Information Table 77. Scorpius BioManufacturing Business Overview Table 78. Scorpius BioManufacturing Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Scorpius BioManufacturing Exosome CDMO Product Portfolio Table 80. Scorpius BioManufacturing Recent Development Table 81. Miltenyi Bioindustry Company Information Table 82. Miltenyi Bioindustry Business Overview Table 83. Miltenyi Bioindustry Exosome CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Miltenyi Bioindustry Exosome CDMO Product Portfolio Table 85. Miltenyi Bioindustry Recent Development Table 86. Exothera Company Information Table 87. Exothera Business Overview Table 88. Exothera Exosome CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Exothera Exosome CDMO Product Portfolio Table 90. Exothera Recent Development Table 91. EXO Biologics Company Information Table 92. EXO Biologics Business Overview Table 93. EXO Biologics Exosome CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. EXO Biologics Exosome CDMO Product Portfolio Table 95. EXO Biologics Recent Development Table 96. Porton Advanced Company Information Table 97. Porton Advanced Business Overview Table 98. Porton Advanced Exosome CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Porton Advanced Exosome CDMO Product Portfolio Table 100. Porton Advanced Recent Development Table 101. Elise Biopharma Company Information Table 102. Elise Biopharma Business Overview Table 103. Elise Biopharma Exosome CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Elise Biopharma Exosome CDMO Product Portfolio Table 105. Elise Biopharma Recent Development Table 106. Evox Therapeutics Company Information Table 107. Evox Therapeutics Business Overview Table 108. Evox Therapeutics Exosome CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Evox Therapeutics Exosome CDMO Product Portfolio Table 110. Evox Therapeutics Recent Development Table 111. FUJIFILM Biotechnologies Company Information Table 112. FUJIFILM Biotechnologies Business Overview Table 113. FUJIFILM Biotechnologies Exosome CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. FUJIFILM Biotechnologies Exosome CDMO Product Portfolio Table 115. FUJIFILM Biotechnologies Recent Development Table 116. North America Exosome CDMO Revenue by Type (2021-2026) & (US$ Million) Table 117. North America Exosome CDMO Revenue by Type (2027-2032) & (US$ Million) Table 118. North America Exosome CDMO Revenue by Application (2021-2026) & (US$ Million) Table 119. North America Exosome CDMO Revenue by Application (2027-2032) & (US$ Million) Table 120. North America Exosome CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. North America Exosome CDMO Revenue by Country (2021-2026) & (US$ Million) Table 122. North America Exosome CDMO Revenue by Country (US$ Million) & (2027-2032) Table 123. Europe Exosome CDMO Revenue by Type (2021-2026) & (US$ Million) Table 124. Europe Exosome CDMO Revenue by Type (2027-2032) & (US$ Million) Table 125. Europe Exosome CDMO Revenue by Application (2021-2026) & (US$ Million) Table 126. Europe Exosome CDMO Revenue by Application (2027-2032) & (US$ Million) Table 127. Europe Exosome CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. Europe Exosome CDMO Revenue by Country (2021-2026) & (US$ Million) Table 129. Europe Exosome CDMO Revenue by Country (US$ Million) & (2027-2032) Table 130. China Exosome CDMO Revenue by Type (2021-2026) & (US$ Million) Table 131. China Exosome CDMO Revenue by Type (2027-2032) & (US$ Million) Table 132. China Exosome CDMO Revenue by Application (2021-2026) & (US$ Million) Table 133. China Exosome CDMO Revenue by Application (2027-2032) & (US$ Million) Table 134. Asia Exosome CDMO Revenue by Type (2021-2026) & (US$ Million) Table 135. Asia Exosome CDMO Revenue by Type (2027-2032) & (US$ Million) Table 136. Asia Exosome CDMO Revenue by Application (2021-2026) & (US$ Million) Table 137. Asia Exosome CDMO Revenue by Application (2027-2032) & (US$ Million) Table 138. Asia Exosome CDMO Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Asia Exosome CDMO Revenue by Region (US$ Million) & (2021-2026) Table 140. Asia Exosome CDMO Revenue by Region (US$ Million) & (2027-2032) Table 141. SAMEA Exosome CDMO Revenue by Type (2021-2026) & (US$ Million) Table 142. SAMEA Exosome CDMO Revenue by Type (2027-2032) & (US$ Million) Table 143. SAMEA Exosome CDMO Revenue by Application (2021-2026) & (US$ Million) Table 144. SAMEA Exosome CDMO Revenue by Application (2027-2032) & (US$ Million) Table 145. SAMEA Exosome CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 146. SAMEA Exosome CDMO Revenue by Country (2021-2026) & (US$ Million) Table 147. SAMEA Exosome CDMO Revenue by Country (US$ Million) & (2027-2032) Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Exosome CDMO Image Figure 2. Global Exosome CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Exosome CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 4. Preclinical CRO Image Figure 5. Clinical CRO Image Figure 6. Global Exosome CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Exosome CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 8. Laboratory Image Figure 9. Universities Image Figure 10. Bio Industry Image Figure 11. Medical Industry Image Figure 12. Global Exosome CDMO Market Size (US$ Million) & (2021-2032) Figure 13. Global Exosome CDMO Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Exosome CDMO Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Exosome CDMO Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Exosome CDMO Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Exosome CDMO Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Exosome CDMO Revenue Market Share by Type (2021-2032) Figure 20. Global Exosome CDMO Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Exosome CDMO Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Exosome CDMO Revenue Market Share by Application (2021-2032) Figure 23. North America Exosome CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Exosome CDMO Revenue Share by Type (2021-2032) Figure 25. North America Exosome CDMO Revenue Share by Application (2021-2032) Figure 26. North America Exosome CDMO Revenue Share by Country (2021-2032) Figure 27. United States Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Exosome CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Exosome CDMO Revenue Share by Type (2021-2032) Figure 32. Europe Exosome CDMO Revenue Share by Application (2021-2032) Figure 33. Europe Exosome CDMO Revenue Share by Country (2021-2032) Figure 34. Germany Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Exosome CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Exosome CDMO Revenue Share by Type (2021-2032) Figure 44. China Exosome CDMO Revenue Share by Application (2021-2032) Figure 45. Asia Exosome CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Exosome CDMO Revenue Share by Type (2021-2032) Figure 47. Asia Exosome CDMO Revenue Share by Application (2021-2032) Figure 48. Asia Exosome CDMO Revenue Share by Region (2021-2032) Figure 49. Japan Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Exosome CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Exosome CDMO Revenue Share by Type (2021-2032) Figure 57. SAMEA Exosome CDMO Revenue Share by Application (2021-2032) Figure 58. SAMEA Exosome CDMO Revenue Share by Country (2021-2032) Figure 59. Brazil Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Exosome CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Preclinical CRO
  • Clinical CRO
Applications
  • Laboratory
  • Universities
  • Bio Industry
  • Medical Industry
Companies covered
  • REPROCELL
  • Histocell
  • Lonza
  • MYCENAX
  • RoosterBio
  • Altaris LLC
  • Asahi Glass Co.
  • Fortis Life Sciences
  • Scorpius BioManufacturing
  • Miltenyi Bioindustry
  • Exothera
  • EXO Biologics
  • Porton Advanced
  • Elise Biopharma
  • Evox Therapeutics
  • FUJIFILM Biotechnologies

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Exosome CDMO Market by Type
  3. 1.2.1 Global Exosome CDMO Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Preclinical CRO
  5. 1.2.3 Clinical CRO
  6. 1.3 Exosome CDMO Market by Application
  7. 1.3.1 Global Exosome CDMO Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Laboratory
  9. 1.3.3 Universities
  10. 1.3.4 Bio Industry
  11. 1.3.5 Medical Industry
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Exosome CDMO Market Dynamics
  1. 2.1 Exosome CDMO Industry Trends
  2. 2.2 Exosome CDMO Industry Drivers
  3. 2.3 Exosome CDMO Industry Opportunities and Challenges
  4. 2.4 Exosome CDMO Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Exosome CDMO Market Perspective (2021-2032)
  2. 3.2 Global Exosome CDMO Growth Trends by Region
  3. 3.2.1 Global Exosome CDMO Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Exosome CDMO Market Size by Region (2021-2026)
  5. 3.2.3 Global Exosome CDMO Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Exosome CDMO Revenue by Players
  2. 4.1.1 Global Exosome CDMO Revenue by Players (2021-2026)
  3. 4.1.2 Global Exosome CDMO Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Exosome CDMO Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Exosome CDMO Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Exosome CDMO Key Players Headquarters & Area Served
  7. 4.4 Global Exosome CDMO Players, Product Type & Application
  8. 4.5 Global Exosome CDMO Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Exosome CDMO Market CR5 and HHI
  11. 4.6.3 2025 Exosome CDMO Tier 1, Tier 2, and Tier 3
5 Exosome CDMO Market Size by Type
  1. 5.1 Global Exosome CDMO Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Exosome CDMO Revenue by Type (2021-2032)
  3. 5.3 Global Exosome CDMO Revenue Market Share by Type (2021-2032)
6 Exosome CDMO Market Size by Application
  1. 6.1 Global Exosome CDMO Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Exosome CDMO Revenue by Application (2021-2032)
  3. 6.3 Global Exosome CDMO Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 REPROCELL
  2. 7.1.1 REPROCELL Company Information
  3. 7.1.2 REPROCELL Business Overview
  4. 7.1.3 REPROCELL Exosome CDMO Revenue and Gross Margin (2021-2026)
  5. 7.1.4 REPROCELL Exosome CDMO Product Portfolio
  6. 7.1.5 REPROCELL Recent Developments
  7. 7.2 Histocell
  8. 7.2.1 Histocell Company Information
  9. 7.2.2 Histocell Business Overview
  10. 7.2.3 Histocell Exosome CDMO Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Histocell Exosome CDMO Product Portfolio
  12. 7.2.5 Histocell Recent Developments
  13. 7.3 Lonza
  14. 7.3.1 Lonza Company Information
  15. 7.3.2 Lonza Business Overview
  16. 7.3.3 Lonza Exosome CDMO Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Lonza Exosome CDMO Product Portfolio
  18. 7.3.5 Lonza Recent Developments
  19. 7.4 MYCENAX
  20. 7.4.1 MYCENAX Company Information
  21. 7.4.2 MYCENAX Business Overview
  22. 7.4.3 MYCENAX Exosome CDMO Revenue and Gross Margin (2021-2026)
  23. 7.4.4 MYCENAX Exosome CDMO Product Portfolio
  24. 7.4.5 MYCENAX Recent Developments
  25. 7.5 RoosterBio
  26. 7.5.1 RoosterBio Company Information
  27. 7.5.2 RoosterBio Business Overview
  28. 7.5.3 RoosterBio Exosome CDMO Revenue and Gross Margin (2021-2026)
  29. 7.5.4 RoosterBio Exosome CDMO Product Portfolio
  30. 7.5.5 RoosterBio Recent Developments
  31. 7.6 Altaris LLC
  32. 7.6.1 Altaris LLC Company Information
  33. 7.6.2 Altaris LLC Business Overview
  34. 7.6.3 Altaris LLC Exosome CDMO Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Altaris LLC Exosome CDMO Product Portfolio
  36. 7.6.5 Altaris LLC Recent Developments
  37. 7.7 Asahi Glass Co.
  38. 7.7.1 Asahi Glass Co. Company Information
  39. 7.7.2 Asahi Glass Co. Business Overview
  40. 7.7.3 Asahi Glass Co. Exosome CDMO Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Asahi Glass Co. Exosome CDMO Product Portfolio
  42. 7.7.5 Asahi Glass Co. Recent Developments
  43. 7.8 Fortis Life Sciences
  44. 7.8.1 Fortis Life Sciences Company Information
  45. 7.8.2 Fortis Life Sciences Business Overview
  46. 7.8.3 Fortis Life Sciences Exosome CDMO Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Fortis Life Sciences Exosome CDMO Product Portfolio
  48. 7.8.5 Fortis Life Sciences Recent Developments
  49. 7.9 Scorpius BioManufacturing
  50. 7.9.1 Scorpius BioManufacturing Company Information
  51. 7.9.2 Scorpius BioManufacturing Business Overview
  52. 7.9.3 Scorpius BioManufacturing Exosome CDMO Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Scorpius BioManufacturing Exosome CDMO Product Portfolio
  54. 7.9.5 Scorpius BioManufacturing Recent Developments
  55. 7.10 Miltenyi Bioindustry
  56. 7.10.1 Miltenyi Bioindustry Company Information
  57. 7.10.2 Miltenyi Bioindustry Business Overview
  58. 7.10.3 Miltenyi Bioindustry Exosome CDMO Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Miltenyi Bioindustry Exosome CDMO Product Portfolio
  60. 7.10.5 Miltenyi Bioindustry Recent Developments
  61. 7.11 Exothera
  62. 7.11.1 Exothera Company Information
  63. 7.11.2 Exothera Business Overview
  64. 7.11.3 Exothera Exosome CDMO Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Exothera Exosome CDMO Product Portfolio
  66. 7.11.5 Exothera Recent Developments
  67. 7.12 EXO Biologics
  68. 7.12.1 EXO Biologics Company Information
  69. 7.12.2 EXO Biologics Business Overview
  70. 7.12.3 EXO Biologics Exosome CDMO Revenue and Gross Margin (2021-2026)
  71. 7.12.4 EXO Biologics Exosome CDMO Product Portfolio
  72. 7.12.5 EXO Biologics Recent Developments
  73. 7.13 Porton Advanced
  74. 7.13.1 Porton Advanced Company Information
  75. 7.13.2 Porton Advanced Business Overview
  76. 7.13.3 Porton Advanced Exosome CDMO Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Porton Advanced Exosome CDMO Product Portfolio
  78. 7.13.5 Porton Advanced Recent Developments
  79. 7.14 Elise Biopharma
  80. 7.14.1 Elise Biopharma Company Information
  81. 7.14.2 Elise Biopharma Business Overview
  82. 7.14.3 Elise Biopharma Exosome CDMO Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Elise Biopharma Exosome CDMO Product Portfolio
  84. 7.14.5 Elise Biopharma Recent Developments
  85. 7.15 Evox Therapeutics
  86. 7.15.1 Evox Therapeutics Company Information
  87. 7.15.2 Evox Therapeutics Business Overview
  88. 7.15.3 Evox Therapeutics Exosome CDMO Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Evox Therapeutics Exosome CDMO Product Portfolio
  90. 7.15.5 Evox Therapeutics Recent Developments
  91. 7.16 FUJIFILM Biotechnologies
  92. 7.16.1 FUJIFILM Biotechnologies Company Information
  93. 7.16.2 FUJIFILM Biotechnologies Business Overview
  94. 7.16.3 FUJIFILM Biotechnologies Exosome CDMO Revenue and Gross Margin (2021-2026)
  95. 7.16.4 FUJIFILM Biotechnologies Exosome CDMO Product Portfolio
  96. 7.16.5 FUJIFILM Biotechnologies Recent Developments
8 North America
  1. 8.1 North America Exosome CDMO Revenue (2021-2032)
  2. 8.2 North America Exosome CDMO Revenue by Type (2021-2032)
  3. 8.2.1 North America Exosome CDMO Revenue by Type (2021-2026)
  4. 8.2.2 North America Exosome CDMO Revenue by Type (2027-2032)
  5. 8.3 North America Exosome CDMO Revenue Share by Type (2021-2032)
  6. 8.4 North America Exosome CDMO Revenue by Application (2021-2032)
  7. 8.4.1 North America Exosome CDMO Revenue by Application (2021-2026)
  8. 8.4.2 North America Exosome CDMO Revenue by Application (2027-2032)
  9. 8.5 North America Exosome CDMO Revenue Share by Application (2021-2032)
  10. 8.6 North America Exosome CDMO Revenue by Country
  11. 8.6.1 North America Exosome CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Exosome CDMO Revenue by Country (2021-2026)
  13. 8.6.3 North America Exosome CDMO Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Exosome CDMO Revenue (2021-2032)
  2. 9.2 Europe Exosome CDMO Revenue by Type (2021-2032)
  3. 9.2.1 Europe Exosome CDMO Revenue by Type (2021-2026)
  4. 9.2.2 Europe Exosome CDMO Revenue by Type (2027-2032)
  5. 9.3 Europe Exosome CDMO Revenue Share by Type (2021-2032)
  6. 9.4 Europe Exosome CDMO Revenue by Application (2021-2032)
  7. 9.4.1 Europe Exosome CDMO Revenue by Application (2021-2026)
  8. 9.4.2 Europe Exosome CDMO Revenue by Application (2027-2032)
  9. 9.5 Europe Exosome CDMO Revenue Share by Application (2021-2032)
  10. 9.6 Europe Exosome CDMO Revenue by Country
  11. 9.6.1 Europe Exosome CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Exosome CDMO Revenue by Country (2021-2026)
  13. 9.6.3 Europe Exosome CDMO Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Exosome CDMO Revenue (2021-2032)
  2. 10.2 China Exosome CDMO Revenue by Type (2021-2032)
  3. 10.2.1 China Exosome CDMO Revenue by Type (2021-2026)
  4. 10.2.2 China Exosome CDMO Revenue by Type (2027-2032)
  5. 10.3 China Exosome CDMO Revenue Share by Type (2021-2032)
  6. 10.4 China Exosome CDMO Revenue by Application (2021-2032)
  7. 10.4.1 China Exosome CDMO Revenue by Application (2021-2026)
  8. 10.4.2 China Exosome CDMO Revenue by Application (2027-2032)
  9. 10.5 China Exosome CDMO Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Exosome CDMO Revenue (2021-2032)
  2. 11.2 Asia Exosome CDMO Revenue by Type (2021-2032)
  3. 11.2.1 Asia Exosome CDMO Revenue by Type (2021-2026)
  4. 11.2.2 Asia Exosome CDMO Revenue by Type (2027-2032)
  5. 11.3 Asia Exosome CDMO Revenue Share by Type (2021-2032)
  6. 11.4 Asia Exosome CDMO Revenue by Application (2021-2032)
  7. 11.4.1 Asia Exosome CDMO Revenue by Application (2021-2026)
  8. 11.4.2 Asia Exosome CDMO Revenue by Application (2027-2032)
  9. 11.5 Asia Exosome CDMO Revenue Share by Application (2021-2032)
  10. 11.6 Asia Exosome CDMO Revenue by Country
  11. 11.6.1 Asia Exosome CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Exosome CDMO Revenue by Country (2021-2026)
  13. 11.6.3 Asia Exosome CDMO Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Exosome CDMO Revenue (2021-2032)
  2. 12.2 SAMEA Exosome CDMO Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Exosome CDMO Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Exosome CDMO Revenue by Type (2027-2032)
  5. 12.3 SAMEA Exosome CDMO Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Exosome CDMO Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Exosome CDMO Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Exosome CDMO Revenue by Application (2027-2032)
  9. 12.5 SAMEA Exosome CDMO Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Exosome CDMO Revenue by Country
  11. 12.6.1 SAMEA Exosome CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Exosome CDMO Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Exosome CDMO Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst